Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06301529 · ClinicalTrials.gov registry record · Phase 4
The Efficacy and Tolerability of Canagliflozin in Healthy Individual
A Phase 4 study, sponsored by AgelessRx.
- Completed
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
NCT06301529 is a Phase 4 study that has completed, run by AgelessRx. The registered enrollment target is 30 participants.
The verdict
NCT06301529, a Phase 4 study, has completed, sponsored by AgelessRx.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
Study Summary
The primary objective is to measure the effects that canagliflozin intervention has on reducing average glucose in healthy individuals. The secondary objective is to assess the tolerability and side effects and urinary glucose excretion following the pulsatile dosing protocol.
Interventions
- DRUG Invokana Pill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-02-12 |
| Est. Completion | 2024-06-29 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06301529
The ClinicalTrials.gov registry entry for NCT06301529 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AgelessRx, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Invokana Pill is the first listed.
NCT06301529 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06301529 about?
NCT06301529 is a clinical study titled "The Efficacy and Tolerability of Canagliflozin in Healthy Individual". The primary objective is to measure the effects that canagliflozin intervention has on reducing average glucose in healthy individuals. The secondary objective is to assess the tolerability and side effects and urinary glucose excretion following the pulsatile dosing protocol.
What is the current status of trial NCT06301529?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2024-02-12. Estimated completion is 2024-06-29.
What interventions are being tested in trial NCT06301529?
The interventions under investigation include: Invokana Pill (DRUG).
Who is sponsoring clinical trial NCT06301529?
This trial is sponsored by AgelessRx, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.